透析依赖患者膝下血运重建的结局:旁路术与腔内治疗的比较
该回顾性研究纳入2005至2024年280例血液透析依赖的慢性肢体威胁性缺血患者,比较膝下旁路术(BPG)与血管成形/支架术(PTA/S)的结局。BPG与较低的2年大截肢风险、5年截肢/死亡及死亡风险相关,单段大隐静脉旁路术的获益更显著。
要点
- 透析依赖CLTI患者膝下血运重建后截肢和死亡风险高,应重视手术耐久性。
- 合适的外科候选者中,BPG与较低的5年截肢/死亡(HR 0.55)和死亡(HR 0.56)风险相关。
- 单段大隐静脉旁路术可提高6个月伤口愈合率(HR 2.40)并降低5年大截肢风险(HR 0.36)。
核心结论
- 血液透析依赖的CLTI患者膝下血运重建后截肢和死亡风险高,但透析护理进步延长了生存,使手术耐久性和保肢策略更受关注。
- 在合适的外科候选者中,BPG与较低的5年截肢/死亡和死亡风险相关,单段大隐静脉旁路术获益更大。
研究设计与样本
- 回顾性队列研究,纳入2005至2024年单中心1468例首次膝下血运重建的CLTI肢体,其中280例为血液透析依赖者。
- 105例接受BPG(87%使用单段大隐静脉),175例接受PTA/S;采用χ2、Kaplan-Meier和Cox回归分析。
主要发现
- 调整后,BPG与2年大截肢风险降低相关(20% vs 32%;HR 0.10,95%CI 0.03-0.40),但5年差异未持续(31% vs 38%;HR 0.37,95%CI 0.13-1.02)。
- BPG与5年截肢/死亡风险降低45%相关(71% vs 83%;HR 0.55,95%CI 0.33-0.90),与死亡风险降低44%相关(66% vs 79%;HR 0.56,95%CI 0.35-0.94)。
- 单段大隐静脉旁路术亚组分析显示6个月完全伤口愈合率更高(41% vs 25%;HR 2.40,95%CI 1.03-5.58),5年大截肢风险更低(27% vs 38%;HR 0.36,95%CI 0.13-0.98)。
临床怎么用
- 对于血液透析依赖的CLTI患者,在仔细选择的外科候选者中可考虑膝下旁路术,尤其是使用高质量单段大隐静脉时。
- 需权衡BPG的早期保护效应与长期耐久性,个体化选择血运重建方式。
局限性
- 回顾性单中心研究,存在选择偏倚可能。
- BPG组更多为高解剖分级(GLASS 4级),可能影响结果解释。
- 单段大隐静脉亚组分析样本量较小,结论需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Hemodialysis-dependent (HD) patients with chronic limb-threatening ischemia (CLTI) often present with complex, multilevel, calcified disease and are among the highest-risk populations undergoing lower extremity revascularization. However, there are limited data evaluating outcomes among this cohort following tibial interventions. We aimed to compare outcomes in patients with CLTI and HD undergoing either infrapopliteal bypass (BPG) or angioplasty with or without stenting (PTA/S). METHODS: All patients with HD undergoing a first-time infrapopliteal BPG or PTA/S for CLTI at our institution from 2005 to 2024 were retrospectively reviewed. Primary outcomes included perioperative complications, wound healing, patency, reintervention, major amputation, and amputation or death (amputation/death). Outcomes were evaluated using χ2, Kaplan-Meier, and Cox regression analyses. RESULTS: Of 1468 limbs undergoing a first-time infrapopliteal intervention for CLTI between 2005 and 2024, 280 had HD, of which 105 underwent BPG (87% ssGSV) and 175 PTA/S. Demographics were largely similar between BPG and PTA/S, with differences seen in non-White race (28% vs 44%) and smoking history (65% vs 44%) (all P < .05). BPG had higher rates of grade 4 femoropopliteal and infrapopliteal Global Limb Anatomic Staging System classification (35% vs 8.0% and 43% vs 28%, respectively) (all P < .05). Unadjusted perioperative outcomes were clinically yet not statistically different, including major amputation (1.0% BPG vs 4.6% PTA/S; P = .09), myocardial infarction (1.0% vs 6.3%; P = .05), and mortality (2.9% vs 6.9%; P = .15), and remained nonsignificant after logistic regression. After adjustment, data demonstrated an early protective effect of BPG against major amputation at 2 years (20% BPG vs 32% PTA/S; hazard ratio [HR], 0.10; 95% confidence interval [CI], 0.03-0.40), without long-term persistence (5-year rates: 31% vs 38%; HR, 0.37; 95% CI, 0.13-1.02). BPG was associated with a 45% lower hazard of amputation/death (5-year rates: 71% vs 83%; HR, 0.55; 95% CI, 0.33-0.90) and 44% lower hazard of death (66% vs 79%; HR, 0.56; 95% CI, 0.35-0.94). A sensitivity analysis restricted to BPG performed with single-segment great saphenous vein (ssGSV) conduit demonstrated even greater benefit of BPG, with significantly greater likelihood of complete wound healing (6-month rates: 41% vs 25%; HR, 2.40; 95% CI, 1.03-5.58) and a lower hazard of major amputation (5-year rates: 27% vs 38%; HR, 0.36; 95% CI, 0.13-0.98), in addition to amputation/death (73% vs 83%; HR, 0.56; 95% CI, 0.34-0.94) and mortality (68% vs 79%; HR, 0.57; 95% CI, 0.33-0.96) compared with PTA/S. CONCLUSIONS: Patients with HD and CLTI undergoing infrapopliteal revascularization face high rates of amputation and mortality, yet contemporary advances in dialysis care have extended survival for many of these patients. As such, procedure durability and limb preservation strategies have become increasingly relevant. Among appropriate surgical candidates, BPG is associated with lower mid- and long-term risk of major amputation, death, and amputation/death. In sensitivity analyses, ssGSV bypass offered even greater benefit, including higher wound healing rates and substantially lower hazards of major amputation, amputation/death, and mortality. These findings support considering BPG-particularly with high-quality ssGSV-in carefully selected HD patients.
引用
- Darling JD, van Galen IF, Guetter CR, et al. Outcomes among hemodialysis-dependent patients undergoing infrapopliteal revascularization for chronic limb-threatening ischemia. J Vasc Surg. 2026. PMID: 41794194. doi:10.1016/j.jvs.2026.02.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。